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Abstract 
Cancer chemotherapy often results in side effects such as high toxicity and drug resistance. 
Sequential and simultaneous delivery of drug combinations have been found to reduce the side 
effects associated with systemic delivery of anticancer drugs. An alternative approach to 
systemic delivery of anticancer drugs is the co-conjugation of two or more these agents to a 
single polymeric carrier via biofissionable linkages. In this study, macromolecular co-
conjugates of bisphosphonate and ferrocene were synthesized and the kinetic drug release 
studied. Phosphorus and proton NMR and FTIR were used to characterize the co-conjugates. 
The mass percentages incorporation of ferrocene analogue were found to be between 4-5 % 
and 10-12 % for bisphosphonate. Kinetic drug release results at selected pH (1.2, 5.5 and 7.4) 
were fitted in different mathematical drug release model to determine the mechanism of release 
of ferrocene and bisphosphonate from a co-conjugate pro-drug. The best model describing the 
release of ferrocene were found to be Korsmeyer-Peppas model at pH 1.2 and zero order model 
at pH 5.5 and 7.4. For bisphosphonate, Korsmeyer-Peppas, Higuchi and zero order models 
were found to best fit the release mechanism at pH 1.2, 5.5 and 7.4 respectively. 
  
Keywords: Ferrocene . Bisphosphonate . Co-conjugate . Macromolecule . Drug release. 
 
*Corresponding author email: Elie.Mukaya@gmail.com 
 
“This article is dedicated to the memory of our colleague Professor Eberhard W. Neuse.” 
1 Introduction 
Bisphosphonates constitute a class of bioactive compounds which exhibit an exceptional 
affinity with bone tissue [1,2]. They have been used in the treatment of paget’s diseases and 
osteoporosis [3,4]. Bisphosphonates have been extensively studied, and they have received 
more attention following the discovery of their antimetastatic activity in cancer patients [5] and 
in the control of tropical diseases such as malaria [6] and sleeping sickness [7]. However, 
bisphosphonates are large, hydrophilic molecule that cannot cross the gastrointestinal 
epithelium via the transcellular route and inefficiently utilize the paracellular route of 
absorption due to their large size and negative charge when administered orally [8]. Thus, 
despite the physiochemical advantage, the oral bioavailability of bisphosphonates remains low 
at 0.6% to 1.5% of the admistered dose [9]. 
The use of ferrocene for medicinal applications has grown fast since its discovery [10]. Many 
reports have shown that some ferrocene derivatives are highly active in vitro and in vivo, 
against several diseases including fungal and bacterial infections [11,12], malaria [13-15] and 
cancer [16-20].  
During the past decade, many research studies focussed on the sequential and simultaneous 
delivery of drug combinations, to reduce the side effects associated with the systemic delivery 
of cancer agents [21]. Several drugs have been found to amplify the anticancer activity of others 
[22]. This synergistic effect could lead to reduced doses for each drug administered [23], 
thereby reducing the side effects caused by the high doses of a single drug, and preventing the 
development of multi-drug resistance [24]. A possible route for the simultaneous delivery of 
anticancer drugs is the co-conjugation of two or more of these compounds to a single polymeric 
carrier. Reports covering this approach are rare. However, the literature extensively reported 
the targeted delivery of a drug system in which a targeting moiety together with a drug is 
anchored to the same polymer [25,26].  
The water soluble, biocompatible and biodegradable macromolecular-drug co-conjugate, 
administered intravenously, offers significant advantages over the free drug, these include: (i) 
Utilization of the enhanced permeability and retention effect [27], which serves to provide 
preferential accumulation of macromolecules (as compared to low –molecular compounds) in 
tumorous tissue. (ii) Temporary protection, while in transit, from premature catabolism, 
enzymatic attack, or serum protein binding, thus increasing circulation life time and 
bioavailability. (iii) Facilitated endocytotic cell entry, thus overcoming problems of drug 
charge and polarity, as well as resistance caused by accelerated drug efflux from affected cell. 
The overall consequence of these features is a widened therapeutic window and enhanced drug 
effectiveness [28].  
The synthesis and utilization of macromolecules of the poly(amidoamine) type in biomedicine, 
pioneered by Ferruti [29,30], has laid fertile ground for pharmaceutical research. Amidoamine 
macromolecules, in which both carboxamide and secondary or tertiary amino groups appear in 
ordered fashion as main-chain constituents, biodegradable, biocompatible (i.e. non-toxic and 
non-immunogenic), and, if properly designed, dissolve readily in aqueous medium. 
Poly(amidoamine) type macromolecules have been used extensively as drug carriers [31,32]. 
In this study, we describe the preparation of poly(amidoamine) co-conjugates containing 
ferrocene analogue and bisphosphonate, and the kinetic drug release study of both drugs from 
the macromolecule.   
2 Experimental 
 2.1 General Procedure 
Dialysis processes were performed with the aid of cellulose membranes tubing (Spectrum 
Industry Inc., Los Angeles, USA) of type Spectra/Por 4 (12 000-14 000 molecular mass cut-
off limit) against several batches of distilled water. Freeze-drying operations were performed 
with the aid of a Virtis Bench Top 3 freeze drier (operating at a temperature of -58oC and a 
pressure of 20-30 mT). The freeze dried polymers were routinely subjected to a post drying in 
an Abderhalden woven at 40oC under vacuum (CaCl2 as drying agent). Inherent viscosities, 
ƞinh, were determined at 30.0 ± 0.5oC in cannon-Fenske viscosimeter tubes. Distilled water was 
used as solvent at a concentratgion of 0.2 g/100 mL. The results, average of three runs, are 
given in units of mL/g. 1H and 31P NMR spectra (400 MHz, Bruker, Germany) were recorded 
using deuterium Oxide (D2O) solution with chemical shifts (δ) in ppm, (integration error limits 
±10%). All samples were adjusted to pH 10-11 with NaOH in order to eliminate protonation 
effects.  
2.2 Solvent and Reagents 
Distilled water was used for all preparative work. All other solvents were laboratory grade, 
received from commercial sources, and all reagents were used as received (Aldrich Chemie, 
Fluka AG). These included: ferrocene, N,N’-methylenebis(acrylamide) (MBA), 
3,3dimethylpropylamine (DMP), 2-(2-aminoethoxy)ethanol (AEE), ethanolamine (EA), 1,3-
diaminopropane (PDA), phosphorous acid (99%), methanesulfonic acid (99%), phosphorous 
trichloride, 6-aminocaproic acid.   
2.3 Synthesis of 4-ferrocenylbutamidopropylamine (Fc-PDA) 
In the first step, ferrocenylbutanoic acid (Fc) was prepared. This ferrocenylation agent was 
prepared according to the procedure described in literature [33]. The isolated Fc was used to 
prepare Fc-PDA (Fig. 1b)according to the following procedure: 
Fc (2.72 g, 10 mmol) was dissolved in 20 mL of THF. HSU (1.38 g, 12 mmol) was added in 
small portions while stirring at room temperature (RT), then in ice-bath. N,N’-
dicyclohexylcarbodiimide (DCC) (2.48 g, 12 mmol) in THF (5 mL) was added drop-wise over 
a period 30 min period. Stirring continued in ice-bath for 4 h, then 48 h at RT. The solid was 
filtered off and washed with THF. The filtrate and washings were combined and added drop-
wise to a stirred solution of PDA (2.99 g, 40 mmol) in THF (20 mL) at ice-bath temperature. 
Stirring continued at ice-bath temperature for 24 h and for another 6 h at RT. The solid was 
removed and washed with THF. The filtrate and washes were combined and spun to an oily 
viscous liquid by rotating evaporation (bath temperature 65 oC). The oily liquid was dissolved 
in MeOH (4 mL) and acidified to pH 3-4 with conc. HCl, then purified by flash chromatography 
(silica gel Column) with MeOH as eluent. The solvent was removed by rotating evaporation. 
The product was viscous at RT and obtained in yield of 1.92 g (58.7 %). 
1H NMR : δ/ppm (expected proton counts in parentheses): 1.9-1.7, 4H (4H, CH2CH2CH2); 2.4-
2.2, 4H (4H, Fc-CH2 CH2, CH2NH2); 2.8-2.9, 2H (2H, CH2CONH2); 3.25-3.1, 2H (2H, 
CONHCH2); 4.1-4.25, 9H (9H, CH, Ferrocenyl).  
2.4 Synthesis of bisphosphonate 
BP (Fig. 1a) was prepared according to general method reported by Kieczykowski et al [34]. 
By the reaction of 6-aminocaproic acid with phosphorous acid and phosphorus trichloride in 
methane sulfonic acid as solvent. This compound was characterized by 1H NMR, 31P NMR and 
FTIR to confirm its isolation.   
1H NMR (D2O/NaOH, 400 MHz): 1.34-1.26 ppm (m, 2H), 1.51-1.43 ppm (m, 2H), 1.62-1.53 
ppm (m, 2H), 1.94-1.82 ppm (m, 2H), 2.61 ppm (t, 7.0 Hz, 2H); 31P (D2O/NaOH, 400 MHz): 
18.98 ppm (s). 
 
2.5 Synthesis of polyamidoamines co-conjugates 
The conventional work-up involved the concentration of the reaction solution on the rotary 
evaporator (bath temperature 50-55 oC) to approximately 7 mL, followed by precipitation with 
a mixture of ethanol/hexane, 1:1 by vol. (20 mL), then washing of the precipitate with hot 
acetone and dissolving the precipitate in distilled H2O (15 mL), and adjusting to pH 8.0 with 
concentrated HCl. 
2.5.1 Co-conjugate 1 
To MBA (1.5417 g, 10 mmol) dissolved in boiling H2O (10 mL), then cooled to room 
temperature (RT) was added bisphosphonate (0.297 g, 1.0 mmol) in H2O (1 mL). The mixture 
was purged and saturated with argon gas. While stirring the mixture was allowed to react for 
8h at 55oC. Thereafter ferrocene (0.272 g,1.0 mmol) was added to the reaction mixture. The 
mixture was resaturated with argon gas and stirring continued for another 12h at 55oC. For the 
last step, DMP (0.8174 g, 8 mmol) was added to the reaction mixture, then resaturated with 
argon gas and stirred for another 48h at 55oC. The conventional work-up was performed and 
the solution was dialyzed in spectra/Por 4 membrane tubing for 2d. The water-soluble 
conjugate was freeze-dried, then post dried at 40oC under vacuum. Co-conjugate 1 was 
obtained as yellow water soluble solid in a yield of 1.330 g (46.3 %) and inherent viscosity of 
15.6 mL.g-1. 
1H NMR (D2O), δ/ppm (expected proton counts in parentheses): 1.1-1.0 ppm 2H (2H, CH2 
BP), 1.45-1.25 ppm 4H (4H, CH2 BP), 1.75-1.45 ppm 23H (22H, CH2CH2CH2, CH2 BP, CH2 
Fc), 2.7-2.2 ppm 164H (160H, CH3N, CH2N, NHCOCH2, CH2 BP, CH2 Fc), 3.2-3.0 ppm 2H 
(2H, CH2 Fc), 4.1-4.0 ppm 4.6H (4.5H, Ferrocenyl), 4.4-3.35 ppm 20H (20H, NHCH2NH); 
31P (D2O): 18.74 ppm (s). 
2.5.2 Co-conjugate 2 
By the procedure leading to co-conjugate 1, co-conjugate 2 was prepared from MBA (1.5417 
g, 10 mmol), bisphosphonate (0.2971 g, 1.0 mmol), ferrocene (0.272 g, 1.0 mmol) and AEE 
(0.8410 g, 8 mmol). The solution was treated and worked up as before, giving 1.211 g (41.8 
%) of 2 as yellow water soluble solid with inherent viscosity of 12.8 mL.g-1. 
1H NMR (D2O), δ/ppm (expected proton counts in parentheses): 1.15-1.05 ppm 2H (2H, CH2 
BP), 1.45-1.25 ppm 4H (4H, CH2 BP), 1.75-1.6 ppm 4H (4H, CH2 BP, CH2 Fc), 2.35-2.2 ppm 
46H (44H, COCH2CH2N, CH2 Fc), 2.7-2.5 ppm 61H (62H, NCH2CH2O, NHCOCH2, CH2 
BP), 3.1-3.0 ppm 2H (CH2 Fc), 3.5-3.4 ppm 34.5H (36H, CH2OCH2), 3.6-3.5 ppm 17H (18H, 
CH2OH), 3.9-4.0 ppm 4.5H (4.5H, Ferrocenyl H), 4.4 ppm 20H (20H, NHCH2NH); 31P (D2O): 
18.94 ppm (s). 
2.5.3 Co-conjugate 3 
An experiment conducted as in the forgoing, MBA (1.5417 g, 10 mmol), BP (0.2971 g, 1.0 
mmol), ferrocene (0.272 g, 1.0 mmol) and EA (0.4886 g, 8 mmol) were used. Co-conjugate 3 
was obtained as yellow water soluble solid in yield of 1.227 g (48.6 %) with inherent viscosity 
of 13.4 mL.g-1. 
1H NMR (D2O), δ/ppm (expected proton counts in parentheses): 1.15-1.05 ppm 2H (2H, CH2 
BP), 1.45-1.30 ppm 4H (4H, CH2 BP), 1.75-1.65 ppm 2H (2H, CH2 BP), 2.35-2.15 ppm 44H 
(42H, COCH2CH2N, CH2 Fc), 2.5-2.4 ppm 21H (20H, NCH2CH2OH), 2.7-2.55 ppm 43H 
(42H, NHCOCH2, CH2), 3.1-3.0 ppm 2H (2H, CH2 Fc), 3.5-3.45 ppm 17H (17H, CH2OH), 
4.0-3.95 ppm 4.5H (4.5H, Ferrocenyl H), 4.3 ppm 20H (20H, NHCH2NH); 31P (D2O/NaOH, 
400 MHz): 18.91 ppm (s). 
2.6 In vitro release studies 
In vitro release mechanism of ferrocene analogue and (6-Amino-1-
hydroxyhexylidene)bisphosphonic acid from polyamidoamine, exemplified by co-conjugate 1, 
was studied at 37 oC. 20 mg of 1 was dissolved in 10 mL of different selected buffer solutions 
with pH values of 1.2, 5.5 and 7.4 and placed in 12000 – 14000 molecular mass cut off tubing. 
The tubing were placed in corresponding buffers (50 mL). The study was performed using a 
shaking water bath WBM-SPL25 supplied by Labcon, South Africa, at 100 RPM. 4 mL of 
sample was collected and replaced with a corresponding volume of the corresponding buffer 
solution in intervals of time. Five standard solutions with concentration raging between 18.6-
371 mM were prepared by dilution of corresponding stock solution of ferrocenylbutanoic acid 
in distilled water. The absorbance of these standard solutions was measured at 400 nm and the 
calibration curve generated. Thereafter, using the same wavelength the absorbance of the 
ferrocene complex released was measured and the corresponding amount determined.  In the 
same manner six standard solutions of BP with concentration ranging between 1.25-49.94 mM 
were prepared by dilution of the corresponding stock in perchloric acid solution (2 M).  The 
standard solutions were mixed with a solution of Fe(III) chloride hexahydrate (4.99 mM) in 
perchloric acid (2 M) and the absorbance of the complex was measured at 300 nm immediately 
after mixing for the calibration curve.  The amount of BP released was determined via complex 
formation with Fe(III) in perchloric acid. The absorbance of the complex formed was measured 
at 300 nm and converted to concentration.   
3 Results and Discussion 
The synthetic strategy chosen for the preparation of the target co-conjugates 1, 2 and 3 involved 
the Michael addition copolymerization of methylenebisacrylamide (MBA) with primary 
amines (Scheme 1). The diamine comonomers were 3,3dimethylpropylamine (DMP), 2-(2-
aminoethoxy)ethanol (AEE), ethanolamine (EA), BP and Fc-PDA. The first three amines were 
used as a means of introducing different hydrosolubilizing moieties; and the last two amines 
were used as co-drugs. Both ferrocene derivative and bisphosphonate contained a terminal 
amino group. Under the experimental conditions chosen, each monomer bearing a terminal 
primary amino group was expected to react difunctionally in the polyaddition reaction. In the 
first addition step, the primary amino group reacted with the vinyl group to generate a 
secondary amino group. Though in principle the secondary amino groups are less reactive than 
the primary amino groups, because of the availability of vinyl groups, the secondary amino 
groups were susceptible to further the polyaddition. Typically the reactions were performed in 
water by allowing MBA and bisphosphonate to copolymerize first, then with Fc-PDA and at 
the end the solubilizing moiety was added. The advantage of the route chosen was that the two 
drugs were incorporated directly into the polymer during polymerization. In this case good 
incorporation are recorded. In another study [35] using MBA and aspartic acid for platinum 
chelation, it was notice that during drug coupling some of the ligands were not anchored to the 
drug and the incorporation was always below 100 %. Sometimes there were a need of 
retreatment of the conjugate with platinating agent. Similar findings were also reported by 
Komane et al [36]. The macromolecular co-conjugates were fractionated and purified by 
dialysis in membrane possessing molecular mass cut off limit of 12000-14000. The yields were 
in the range of 41-48 % and the inherent viscosities were in the range of 12-16 mL.g-1 for an 
average of three measurements. The drug contents in the co-conjugates were determined by 
both 1H NMR and UV-vis spectroscopy and were found to be in the range of 4-5 % for 
ferrocene and 10-12 % for bisphosphonate which represent 100 % incorporation for both drugs 
based on the structures in scheme 1. Both methods of analysis gave almost similar results with 
a small difference not exceeding 2 %. The 1H NMR spectra of co-conjugates 1, 2 and 3 showed 
the proton signals of the MBA methylene bridge (4.5-4.4 ppm), protons of ferrocenyl (4.1-4.0 
ppm), protons of the bisphosphonate (1.45-1.05 ppm) and the remaining proton groups (3.6-
2.0 ppm) in the expected area ratios. The 31P NMR spectra showed a phosphorus signal (18.98 
ppm) as a singlet. From 1H NMR data, the x/y/z ratios of hydrosolubilizing to bisphosphonate 
to ferrocene groups were deduced and this correlated with the proposed structures. Further 
corroboration was obtained by using FTIR recorded by using the KBr pellet.  
The FTIR spectrum of BP revealed characteristic peaks at wavenumber 802, 1180 and 1140 
cm-1, corresponding to P-C, P-OH and P=O stretching respectively and these peaks were also 
recorded in the spectra of the co-conjugates. Likewise, the FTIR spectrum of Fc-PDA showed 
characteristic peaks at 1705 cm-1 corresponding to C=O band as well as CH bending  for 
ferrocenyl at 810 cm-1 which were also revealed in the co-conjugates. The broad band in the 
region of 3400-3200 cm-1 was assigned to OH group, while the presence of amide band was 
noticeable at 1530 cm-1. A tertiary amine band was noticed at 1400-1340 cm-1 as well as the 
ether (C-O-C) band at 1060 cm-1. These findings confirmed the successful preparation of the 
co-conjugates.   
The kinetic drug release of co-conjugate 1 was performed at pH 1.2, 5.5 and 7.4, simulating 
gastric pH, cancer cells pH and blood serum pH respectively. Co-conjugate 1 was used as to 
demonstrate the mechanism of release of two different drugs from the same carrier. The study 
was performed over a period of 72 h and the percentage drug release was calculated using 
equation 1: 
DR =  
𝑀𝑡
𝑀𝑜
 𝑥 100                                                                                                                      (1) 
Where DR is the % of a specific drug released, Mt is the mass of a specific drug in the buffer 
solution at time t and Mo is the initial mass of specific drug in the co-conjugate. The drug 
release trend was similar for both ferrocene and bisphosphonate at different pH. After 24 h, 
around 72 %, 18 % and 2 % of ferrocene were release at pH 1.2, 5.5 and 7.4 respectively, while 
63 %, 13 % and 3 % of bisphosphonate were released after the same period. The rate of release 
was found to be faster at pH 1.2 and slower at pH 7.4 for both drugs, with 100 % drug release 
at pH 1.2 after 72 h and only 11 % of ferrocene and 14 % of bisphosphonate were released at 
pH 7.4 after 72 h. Since the release was via the amide bond which is sensitive to pH, these 
observations support the suggestion by Neuse [37], that the polymer conjugate will circulate in 
blood serum and will only deliver the active compound at the site of action, and the release can 
be done enzymatically or hydrolytically. 
In order to understand and determine the kinetic release mechanism of ferrocene and 
bisphosphonate from the pro-drug, selected mathematical release model (zero order, first order, 
Higuchi and Korsmeyer-Peppas) were used and the release data obtained at different pH were 
fitted in the selected equations.  
Zero order release mechanism is applicable to system in which the rate of drug release is 
independent of the concentration of the drug within a pharmaceutical dosage and time, and 
equation 2 is used [38].  
Q = Qo + K.t                                                                                                                            (2) 
Where Q is the cumulative amount of drug released at time t, Qo is the initial amount of drug 
in the solution (most times Qo = 0), K is the zero order release constant and t is the time in 
hours. 
Higuchi release mechanism is applicable to system in which the drug release is by diffusion, 
and equation 4 is used [39]. 
Q = K.√𝑡                                                                                                                                  (4) 
Where Q is the cumulative amount of drug released at time t, K is the Higuchi released constant 
and t is the time.  
Korsmeyer-Peppas release model is used to describe drug release from polymeric system, and 
equation 5 is used [40]. 
Q = K.tn                                                                                                                                  (5) 
Where Q is the fraction of drug released at time t, K is the release rate constant, n is the release 
exponent and t is the time. The diffusion exponent (n) is used to determine the release 
mechanism[40]. In this model, 0.45 ≤ n corresponds Fickian diffusion mechanism, 0.45 < n < 
0.89 corresponds anomalous or non-Fickian transport and n = 0.89 corresponds to case II 
(relaxational) transport while n > 0.89 corresponds to super case II transport [41]. The release 
exponent n was determined from the plot Log Mt/M versus Log t for the first 60 % drug release. 
The analysis of Figs 5-10 shows that, the kinetic release mechanism is highly pH dependent. 
For both ferrocene and bisphosphonate the release was faster at pH 1.2 and pH 5.5, and slower 
at pH 7.4. 100 % of both ferrocene and bisphosphonate were released after 72 h at pH 1.2, and 
11 % of ferrocene and 14 % of bisphosphonate were released after the same period of time at 
pH 7.4. For 60 % of drug to be released it needed 18 h at pH 1.2 and 50 h at pH 5.5.  The 
mechanism of release of ferrocene from the co-conjugate followed Korsmeyer-Peppas model 
at pH 1.2, with a goodness of fit of R2 = 0.9979 and a diffusion exponent of n = 0.46. In light 
of these findings, the release of ferrocene corresponded to anomalous or non-Fickian transport. 
At pH 5.5 and 7.4 the best fit corresponded to a zero order release mechanism with R2 of 0.9583 
and 0.9026, and K of 0.0184 and 0.0026 respectively. With regards to bisphosphonate, the 
release was a Fikian diffusion mechanism, with n = 0.45 and R2 = 0.9875 at pH 1.2 and the 
other model did not indicate a good fit. The Higuchi release mechanism which is a diffusion 
drug release was noticed at pH 5.5 with K = 0.91 and R2 = 0.9886. At pH 7.4 only 13.4 % of 
drug was released after 72 h. R2 was 0.9195 for zero order release mechanism and the other 
investigated models did not indicate good linearity (see Table 1).  
4 Conclusion 
Macromolecular co-conjugates containing bisphosphonate and ferrocene complex were 
synthesized. The mass percentages incorporation of ferrocene complex and bisphosphonate 
were found to be in the range of 4-5 % and 15-18 % respectively. Both ferrocene complex and 
bisphosphonate were released during the study. The release of both drugs was found to be faster 
pH 1.2, moderate at pH 5.5, and slower at pH 7.4. The best model describing the kinetic release 
of ferrocene complex were Korsmeyer-Peppas model indicating an anomalous or non-Fickian 
transport at pH 1.2. At pH 5.5 and 7.4, the results suggested a zero order release mechanism. 
With bisphosphonate, Korsmeyer-Peppas model was also noticed at pH 1.2, but a Fikian 
diffusion mechanism. At pH 5.5 it was the Higuchi release model indicating a diffusion 
mechanism and a zero order release mechanism was noticed at pH 7.4.  
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Scheme 1: Synthesis of co-conjugates 1, 2 and 3 
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Fig. 1: (a) Structure of Bisphosphonate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) 
(BP); (b) Structure of 4-ferrocenylbutamidopropylamine (Fc-PDA)  
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Fig. 2 FTIR spectrum of co-conjugate 1 
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Fig. 3 FTIR spectrum of co-conjugate 2 
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Fig. 4 FTIR spectrum of co-conjugate 3 
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Fig. 5 Zero order cumulative release profile of ferrocene.  
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Fig. 6 Zero order cumulative release profile of bisphosphonate 
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Fig. 7 Higuchi release profile of ferrocene. 
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Fig. 8 Higuchi release profile of bisphosphonate  
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Fig. 9 Korsmeyer-Peppas release profile of ferrocene. 
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Fig. 10 Korsmeyer-Peppas release profile of bisphosphonate.  
 
 
Table 1 K and n constants, and R2 for bisphosphonate (BP) and ferrocene complex (Fc) at pH 
1.2, 5.5 and 7.4 for different drug release model 
                                                                                                                                          
                                                                  pH 1.2                      pH 5.5                          pH 7.4 
Drug release Model                  Drug        R2             K or n         R2            K or n          R2             K or n 
Zero order mechanism             BP           0.9619      0.019         0.9778      0.0168        0.9112      0.0027 
                                                 Fe-c         0.7984      0.017         0.9583      0.020          0.9026      0.010 
Higuchi mechanism                 BP           0.988        1.31           0.9895      0.169          0.819        0.161  
                                                 Fe-c         0.9243      1.41          0.8728       1.32            0.7896      0.18     
Korsmeyer-Peppas                  BP            0.9922      0.45          0.9782       0.44            0.8281      0.44 
mechanism                              Fe-c          0.9779      0.46          0.9135       0.99            0.7822      0.69  
 
 
   
  
